Eli Lilly and Company currently carries an SIA SMAX Score of 1 out of 10, indicating minimal alignment across SIA technical and relative strength indicators. The stock appears in the SIA S&P 100 Index Report, where it is currently positioned at 63 out of 103. Relative positioning has weakened, with LLY declining 26 positions over the past month and 46 positions over the past quarter.
From a technical perspective, initial 3-box reversal resistance is identified at $994.55, followed by additional resistance near $1120.03 based on recent highs. On the downside, prior support at $937.19 has been broken, with new support established at $883.13 and further support at $784.20. The most recent Point & Figure signal registered a bearish spread double bottom, suggesting continued technical pressure.
Over the past month, LLY has declined 10.94%, with a 14.77% decline over the past quarter. By comparison, the S&P 100 Index benchmark (EWIOEF) declined 4.45% over the past month and 2.51% over the past quarter.
Sector dynamics may also be influencing performance trends. The Drugs sector is currently positioned as neutral within the SIA Sector Report and has declined 5 positions over the past quarter, indicating some softening in relative strength across the group.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products across the United States and internationally. The company focuses on advancing medicines that address a range of health conditions, with a long history of innovation aimed at improving outcomes and expanding access to treatment worldwide.
Disclaimer: SIACharts Inc. specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment whatsoever. This information has been prepared without regard to any particular investors investment objectives, financial situation, and needs. None of the information contained in this document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. As such, advisors and their clients should not act on any recommendation (express or implied) or information in this report without obtaining specific advice in relation to their accounts and should not rely on information herein as the primary basis for their investment decisions. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources, believed to be reliable. SIACharts Inc. nor its third party content providers make any representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein and shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.
